New funding: Vancouver, Wash.-based biotech company AbSci raised $125 million in a round led by Casdin Capital and Redmile Group. The tech: Founded in 2011, AbSci’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin. The idea is to reduce failure rates and accelerate development of protein biomanufacturing. A big year: AbSci raised a $65 million Series E round in October. In January it acquired Denovium, a small startup that uses deep learning to analyze the function and behavior of proteins.